

Metabolic Modulator Perhexiline Corrects Energy Deficit Capacity in Symptomatic Hypertrophic Cardiomyopathy

Circulation

122, 1562-1569

DOI: [10.1161/circulationaha.109.934059](https://doi.org/10.1161/circulationaha.109.934059)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Reconciling the Protean Manifestations of Arrhythmogenic Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2010, 3, 566-570.	2.1	9
3	Perhexiline and Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2010, 122, 1547-1549.	1.6	34
4	Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. <i>European Journal of Heart Failure</i> , 2011, 13, 1283-1289.	2.9	49
5	Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 1123-1137.	2.3	83
6	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. <i>Heart Rhythm</i> , 2011, 8, 1308-1339.	0.3	995
7	Inherited Cardiomyopathies. <i>New England Journal of Medicine</i> , 2011, 364, 1643-1656.	13.9	430
8	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). <i>Europace</i> , 2011, 13, 1077-1109.	0.7	699
9	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2010. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2011, 25, 6-15.	0.6	6
10	Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy. <i>Yearbook of Sports Medicine</i> , 2011, 2011, 229-231.	0.0	0
11	Effects of Aging, Renal Dysfunction, Left Ventricular Systolic Impairment, and Weight on Steady State Pharmacokinetics of Perhexiline. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 251-256.	1.0	5
12	Clinical Cardiac Magnetic Resonance Spectroscopy. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 320-327.	1.6	34
13	Targeting fatty acid and carbohydrate oxidation â€” A novel therapeutic intervention in the ischemic and failing heart. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011, 1813, 1333-1350.	1.9	298
15	Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial. <i>Trials</i> , 2011, 12, 140.	0.7	13
16	Disease Pathways and Novel Therapeutic Targets in Hypertrophic Cardiomyopathy. <i>Circulation Research</i> , 2011, 109, 86-96.	2.0	153
18	Almanac 2011: cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. <i>Heart</i> , 2011, 97, 1914-1919.	1.2	1
19	Modulating fatty acid oxidation in heart failure. <i>Cardiovascular Research</i> , 2011, 90, 202-209.	1.8	204
20	Metabolic modulation in heart failure: high time for a definitive clinical trial. <i>Heart</i> , 2011, 97, 267-268.	1.2	7
22	A network-oriented perspective on cardiac calcium signaling. <i>American Journal of Physiology - Cell Physiology</i> , 2012, 303, C897-C910.	2.1	15

#	ARTICLE	IF	CITATIONS
23	Agonist-Induced Hypertrophy and Diastolic Dysfunction Are Associated With Selective Reduction in Glucose Oxidation. <i>Circulation: Heart Failure</i> , 2012, 5, 493-503.	1.6	136
24	A Case Series of Concomitant Treatment of Perhexiline With Amiodarone. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 227-231.	1.0	1
26	Mitochondria as a Drug Target in Ischemic Heart Disease and Cardiomyopathy. <i>Circulation Research</i> , 2012, 111, 1222-1236.	2.0	226
27	Patterns of Disease Progression in Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2012, 5, 535-546.	1.6	258
28	Ventricular arrhythmias complicating hypertrophic cardiomyopathy. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012, 73, 502-508.	0.2	2
29	Insights and challenges in hypertrophic cardiomyopathy, 2012. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2012, 23, 174-185.	0.3	7
30	Almanac 2011: Cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2012, 31, 255-261.	0.2	0
31	Almanac 2011: Cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. <i>Revista Portuguesa De Cardiologia</i> , 2012, 31, 255-261.	0.2	1
32	Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. <i>European Heart Journal</i> , 2012, 33, 1724-1733.	1.0	141
33	The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2012, 14, 12.	1.6	141
34	Mechanisms of disease: hypertrophic cardiomyopathy. <i>Nature Reviews Cardiology</i> , 2012, 9, 91-100.	6.1	181
35	Allopurinol for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 809-812.	1.2	15
36	Medical, Surgical and Interventional Management of Hypertrophic Cardiomyopathy With Obstruction. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 665-678.	0.4	6
37	Hypertrophic Cardiomyopathy in Infants and Children. , 0, , .		0
38	Heart failure with normal ejection fraction: a growing pandemic. <i>Future Cardiology</i> , 2012, 8, 383-392.	0.5	2
39	Genetics of inherited cardiomyopathy. <i>European Heart Journal</i> , 2012, 33, 296-304.	1.0	146
40	Myosin binding protein C: implications for signal-transduction. <i>Journal of Muscle Research and Cell Motility</i> , 2012, 33, 31-42.	0.9	32
41	Almanac 2011: Cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. <i>Egyptian Heart Journal</i> , 2012, 64, 17-24.	0.4	0

#	ARTICLE	IF	CITATIONS
42	Prevention of aortic valve stenosis: A realistic therapeutic target?. , 2012, 135, 78-93.		19
43	Cardiac metabolism in hypertrophy and heart failure: implications for therapy. Heart Failure Reviews, 2013, 18, 595-606.	1.7	19
44	Cardiac Metabolism and its Interactions With Contraction, Growth, and Survival of Cardiomyocytes. Circulation Research, 2013, 113, 603-616.	2.0	591
45	ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study). Netherlands Heart Journal, 2013, 21, 567-571.	0.3	15
46	Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 857-865.	1.9	111
47	Hypertrophic, Restrictive, and Infiltrative Cardiomyopathies. , 2013, , 332-341.		0
48	Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome. Journal of Molecular and Cellular Cardiology, 2013, 55, 27-30.	0.9	29
49	Myocardial energetics in heart failure. Basic Research in Cardiology, 2013, 108, 358.	2.5	117
50	Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: insights from positron emission tomography. European Heart Journal Cardiovascular Imaging, 2013, 14, 95-101.	0.5	44
51	Progress in the Molecular Genetics of Hypertrophic Cardiomyopathy: A Mini-Review. Gerontology, 2013, 59, 199-205.	1.4	27
53	Mechanical and energetic properties of papillary muscle from ACTC<i>E99K</i> transgenic mouse models of hypertrophic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H1513-H1524.	1.5	25
54	Focal Energy Deprivation Underlies Arrhythmia Susceptibility in Mice With Calcium-Sensitized Myofilaments. Circulation Research, 2013, 112, 1334-1344.	2.0	42
55	Hypertrophic cardiomyopathy: The need for randomized trials. Global Cardiology Science & Practice, 2013, 2013, 31.	0.3	10
56	Heart failure with preserved ejection fraction: future directions in medical treatment. Expert Review of Cardiovascular Therapy, 2013, 11, 1085-1087.	0.6	0
57	Are We Nearly There Yet? Progress in the Prevention of Sudden Cardiac Death in the Young. Cardiology, 2014, 127, 265-274.	0.6	1
58	Cardiac Energetic Impairment in Heart Disease and the Potential Role of Metabolic Modulators. Circulation: Cardiovascular Genetics, 2014, 7, 720-728.	5.1	18
59	Hypertrophic cardiomyopathy: a heart in need of an energy bar?. Frontiers in Physiology, 2014, 5, 309.	1.3	41
60	Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovascular Research, 2014, 103, 248-257.	1.8	88

#	ARTICLE	IF	CITATIONS
61	Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. <i>Future Cardiology</i> , 2014, 10, 693-698.	0.5	11
62	Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 789-795.	1.1	9
63	Hypertrophic cardiomyopathy in adults: An overview. <i>Journal of the American Association of Nurse Practitioners</i> , 2014, 26, 465-470.	0.5	3
64	Hypertrophic Cardiomyopathy: A Review. <i>Clinical Medicine Insights: Cardiology</i> , 2014, 8s1, CMC.S15717.	0.6	37
65	Muscle dysfunction in hypertrophic cardiomyopathy: What is needed to move to translation?. <i>Journal of Muscle Research and Cell Motility</i> , 2014, 35, 37-45.	0.9	18
66	Cardiovascular remodelling in coronary artery disease and heart failure. <i>Lancet, The</i> , 2014, 383, 1933-1943.	6.3	589
67	Metabolic Impairment in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1388-1400.	1.2	196
68	Nanoscale three-dimensional imaging of the human myocyte. <i>Journal of Structural Biology</i> , 2014, 188, 55-60.	1.3	14
69	Pharmacological approaches to coronary microvascular dysfunction. , 2014, 144, 283-302.		22
70	A straightforward guide to the sarcomeric basis of cardiomyopathies. <i>Heart</i> , 2014, 100, 1916-1923.	1.2	42
71	Caloric restriction mimetics: towards a molecular definition. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 727-740.	21.5	200
72	Management of Symptomatic Hypertrophic Cardiomyopathy: Pills, Alcohol, or the Scalpel?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 341-344.	0.4	3
73	Tratamiento de la miocardiopatía hipertrófica sintomática: ¿pastillas, alcohol o bisturí?. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 341-344.	0.6	5
74	Impairments in mitochondrial palmitoyl-CoA respiratory kinetics that precede development of diabetic cardiomyopathy are prevented by resveratrol in ZDF rats. <i>Journal of Physiology</i> , 2014, 592, 2519-2533.	1.3	44
75	Metabolic imaging of the human heart: clinical application of magnetic resonance spectroscopy. <i>Heart</i> , 2014, 100, 881-890.	1.2	29
76	Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction. <i>European Heart Journal</i> , 2015, 36, 1547-1554.	1.0	53
77	Impaired cardiac mitochondrial oxidative phosphorylation and enhanced mitochondrial oxidative stress in feline hypertrophic cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 308, H1237-H1247.	1.5	40
78	INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on) Tj ETQq1 1 0.784314 rgBT /Over 2015, 2015, 7.	0.3	11

#	ARTICLE	IF	CITATIONS
79	Doppler Systolic Signal Void in Hypertrophic Cardiomyopathy: Apical Aneurysm and Severe Obstruction without Elevated Intraventricular Velocities. Journal of the American Society of Echocardiography, 2015, 28, 1462-1473.	1.2	20
80	Angina treatments and prevention of cardiac events: an appraisal of the evidence: Table 1. European Heart Journal Supplements, 2015, 17, G10-G18.	0.0	6
81	Can RAS inhibitors affect the course of hypertrophic cardiomyopathy?. Lancet Diabetes and Endocrinology, 2015, 3, 95-96.	5.5	1
82	17 β -estradiol prevents cardiac diastolic dysfunction by stimulating mitochondrial function: A preclinical study in a mouse model of a human hypertrophic cardiomyopathy mutation. Journal of Steroid Biochemistry and Molecular Biology, 2015, 147, 92-102.	1.2	47
83	Targets for therapy in sarcomeric cardiomyopathies. Cardiovascular Research, 2015, 105, 457-470.	1.8	122
84	Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Archives of Toxicology, 2015, 89, 1401-1438.	1.9	492
85	Cardiac Cytoarchitecture. , 2015, , .		4
86	Improvement in Cardiac Energetics by Perhexiline in Heart Failure Due to Dilated Cardiomyopathy. JACC: Heart Failure, 2015, 3, 202-211.	1.9	77
87	Hypertrophic Cardiomyopathy. Anesthesia and Analgesia, 2015, 120, 554-569.	1.1	87
88	Cardiac Energy Metabolic Alterations in Pressure Overload-Induced Left and Right Heart Failure (2013) Tj ETQq1 1 0.784314 rgBT /Ov	0.8	45
89	The effect of perhexiline on myocardial protection during coronary artery surgery: a two-centre, randomized, double-blind, placebo-controlled trial. European Journal of Cardio-thoracic Surgery, 2015, 47, 464-472.	0.6	6
90	Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium. European Journal of Clinical Pharmacology, 2015, 71, 1485-1491.	0.8	10
91	Inherited cardiomyopathies- Novel therapies. , 2015, 155, 36-48.		14
92	Metabolic abnormalities of the heart in type II diabetes. Diabetes and Vascular Disease Research, 2015, 12, 239-248.	0.9	36
93	Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy. Molecular BioSystems, 2015, 11, 564-573.	2.9	34
94	Multicentre double-blind randomized controlled trial of perhexiline as a metabolic modulator to augment myocardial protection in patients with left ventricular hypertrophy undergoing cardiac surgery. European Journal of Cardio-thoracic Surgery, 2015, 48, 354-362.	0.6	9
95	Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats. Xenobiotica, 2015, 45, 3-9.	0.5	3
96	Cardiac Metabolism - The Link to Clinical Practice. , 2016, , 191-205.		0

#	ARTICLE	IF	CITATIONS
97	Mechanotransduction and Metabolism in Cardiomyocyte Microdomains. <i>BioMed Research International</i> , 2016, 2016, 1-17.	0.9	30
98	Discovery and Characterization of Novel Anti-schistosomal Properties of the Anti-anginal Drug, Perhexiline and Its Impact on <i>Schistosoma mansoni</i> Male and Female Reproductive Systems. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004928.	1.3	21
99	Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 73-78.	1.0	12
100	Assessment of the Physiological Adaptations to Chronic Hypoxemia in Eisenmenger Syndrome. <i>Congenital Heart Disease</i> , 2016, 11, 341-347.	0.0	4
103	Metabolic Dysfunction in Heart Failure: Diagnostic, Prognostic, and Pathophysiologic Insights From Metabolomic Profiling. <i>Current Heart Failure Reports</i> , 2016, 13, 119-131.	1.3	83
105	Nuclear Imaging for Assessment of Myocardial Perfusion, Metabolism, and Innervation in Hypertrophic Cardiomyopathy. <i>Current Cardiovascular Imaging Reports</i> , 2016, 9, 1.	0.4	1
106	Update on hypertrophic cardiomyopathy and a guide to the guidelines. <i>Nature Reviews Cardiology</i> , 2016, 13, 651-675.	6.1	110
107	Emerging drugs for the treatment of angina pectoris. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 365-376.	1.0	13
108	Pleiotropic mechanisms of action of perhexiline in heart failure. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 1049-1059.	2.4	16
109	Exercise Intolerance In Heart Failure With Preserved Ejection Fraction. <i>Methodist DeBakey Cardiovascular Journal</i> , 2016, 12, 105-109.	0.5	13
110	Carbohydrate and fatty acid perturbations in the amniotic fluid of the recipient twin of pregnancies complicated by twin-twin transfusion syndrome in relation to treatment and fetal cardiovascular risk. <i>Placenta</i> , 2016, 44, 6-12.	0.7	9
111	Apical hypertrophic cardiomyopathy: Present status. <i>International Journal of Cardiology</i> , 2016, 222, 745-759.	0.8	63
112	Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. <i>European Journal of Heart Failure</i> , 2016, 18, 1106-1118.	2.9	101
113	Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. <i>British Journal of Pharmacology</i> , 2016, 173, 1911-1924.	2.7	14
114	Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy. <i>Nature Reviews Cardiology</i> , 2016, 13, 677-687.	6.1	23
115	Metabolic support for the heart: complementary therapy for heart failure?. <i>European Journal of Heart Failure</i> , 2016, 18, 1420-1429.	2.9	81
116	Cardiac-specific downregulation of carnitine palmitoyltransferase-1b (CPT-1b) prevents cardiac remodeling in obese mice. <i>Obesity</i> , 2016, 24, 2533-2543.	1.5	16
117	Sex-related differences in the associations between plasma free fatty acid levels and clinical features in patients with hypertrophic cardiomyopathy. <i>Biology of Sex Differences</i> , 2016, 7, 63.	1.8	2

#	ARTICLE	IF	CITATIONS
118	Drugs that Affect Cardiac Metabolism: Focus on Perhexiline. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 399-405.	1.3	21
119	Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2016, 9, e002764.	1.6	51
121	Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 909-915.	0.8	67
122	Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy. <i>Heart and Vessels</i> , 2017, 32, 166-174.	0.5	17
123	Linking myofilaments to sudden cardiac death: recent advances. <i>Journal of Physiology</i> , 2017, 595, 3939-3947.	1.3	5
124	Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2780-2789.	2.9	7
125	Pharmacological inhibition of carnitine palmitoyltransferase 1 restores mitochondrial oxidative phosphorylation in human trifunctional protein deficient fibroblasts. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 1292-1299.	1.8	10
126	A Good Heart Is Hard to Find. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	0
127	Disease Stage-Dependent Changes in Cardiac Contractile Performance and Oxygen Utilization Underlie Reduced Myocardial Efficiency in Human Inherited Hypertrophic Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	41
128	Metabolic Modulators in Heart Disease: Past, Present, and Future. <i>Canadian Journal of Cardiology</i> , 2017, 33, 838-849.	0.8	111
129	Cardiovascular homeostasis dependence on MICU2, a regulatory subunit of the mitochondrial calcium uniporter. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9096-E9104.	3.3	48
130	Targeting High Oxygen Consumption to Prevent Cardiac Dysfunction in Patients With Aortic Valve Stenosis. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	0
131	Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2186-2200.	1.2	159
132	Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy. <i>Heart Failure Reviews</i> , 2017, 22, 879-888.	1.7	20
133	New Developments in Hypertrophic Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1254-1265.	0.8	27
134	The validation of an LC-MS/MS assay for perhexiline and major hydroxy metabolites, and its application to therapeutic monitoring in patient plasma. <i>Bioanalysis</i> , 2017, 9, 1011-1025.	0.6	3
135	Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure. <i>Diseases (Basel, Switzerland)</i> , 2017, 5, 14.	1.0	34
136	Treatments for Heart Failure. , 2017, , 628-662.		2

#	ARTICLE	IF	CITATIONS
137	MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. <i>European Journal of Endocrinology</i> , 2018, 178, R127-R139.	1.9	52
138	Rest and Stress Longitudinal Systolic Left Ventricular Mechanics in Hypertrophic Cardiomyopathy: Implications for Prognostication. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 578-586.	1.2	12
139	Clinical and Molecular Aspects of Cardiomyopathies. <i>Heart Failure Clinics</i> , 2018, 14, 161-178.	1.0	3
140	Cardiac metabolism – A promising therapeutic target for heart failure. , 2018, 182, 95-114.		64
141	Clinical presentations of hypertrophic cardiomyopathy and implications for therapy. <i>Global Cardiology Science & Practice</i> , 2018, 2018, 19.	0.3	3
142	Current Perspectives on Cardiomyopathies. , 0, , .		0
143	Novel pharmacological approaches for paediatric hypertrophic cardiomyopathy. <i>Progress in Pediatric Cardiology</i> , 2018, 51, 46-54.	0.2	0
144	Novel Pharmacotherapy in Hypertrophic Cardiomyopathy. <i>Cardiology in Review</i> , 2018, 26, 239-244.	0.6	11
145	Translating emerging molecular genetic insights into clinical practice in inherited cardiomyopathies. <i>Journal of Molecular Medicine</i> , 2018, 96, 993-1024.	1.7	11
146	Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00406.	1.1	3
147	Metabolic remodelling in heart failure. <i>Nature Reviews Cardiology</i> , 2018, 15, 457-470.	6.1	392
148	Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. <i>Cardiovascular Research</i> , 2018, 114, 1273-1280.	1.8	64
149	Modeling Hypertrophic Cardiomyopathy: Mechanistic Insights and Pharmacological Intervention. <i>Trends in Molecular Medicine</i> , 2019, 25, 775-790.	3.5	39
150	Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5034.	1.8	187
151	Unlocking the Secrets of Mitochondria in the Cardiovascular System. <i>Circulation</i> , 2019, 140, 1205-1216.	1.6	91
152	Novel Therapies for Prevention and Early Treatment of Cardiomyopathies. <i>Circulation Research</i> , 2019, 124, 1536-1550.	2.0	47
153	Reproducibility of human cardiac phosphorus MRS (³¹ P-MRS) at 7T. <i>NMR in Biomedicine</i> , 2019, 32, e4095.	1.6	22
154	Supplemental thiamine for the treatment of acute heart failure syndrome: a randomized controlled trial. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 96.	3.7	15

#	ARTICLE	IF	CITATIONS
155	Pirfenidone in Heart Failure with Preserved Ejection Fractionâ€”Rationale and Design of the PIROUETTE Trial. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 461-470.	1.3	48
156	Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment. <i>Heart Failure Reviews</i> , 2019, 24, 439-459.	1.7	48
157	Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy. <i>JAMA Cardiology</i> , 2019, 4, 230.	3.0	47
158	Extra energy for hearts with a genetic defect: ENERGY trial. <i>Netherlands Heart Journal</i> , 2019, 27, 200-205.	0.3	12
159	Cardiac Magnetic Resonance Spectroscopy. , 2019, , 97-107.e6.		2
160	Metabolic Alterations in Inherited Cardiomyopathies. <i>Journal of Clinical Medicine</i> , 2019, 8, 2195.	1.0	28
161	Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles. <i>Nature Reviews Cardiology</i> , 2019, 16, 33-55.	6.1	188
162	Novel Pharmacotherapy for Hypertrophic Cardiomyopathy. <i>Cardiology Clinics</i> , 2019, 37, 113-117.	0.9	0
163	Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 157-167.	0.5	92
164	Medical Therapy: From Beta-Blockers to Disopyramide. , 2019, , 199-219.		0
165	Novel Medical Therapeutics for Hypertrophic Cardiomyopathy. , 2019, , 383-387.		0
166	Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits. <i>Antioxidants and Redox Signaling</i> , 2019, 31, 318-358.	2.5	49
167	Current State of Hypertrophic Cardiomyopathy Clinical Trials. <i>Global Heart</i> , 2019, 14, 317.	0.9	14
168	Genetic Cardiomyopathies. , 2020, , 77-114.		1
169	Hypertrophic cardiomyopathy: the future of treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 228-240.	2.9	93
170	Altered mitochondrial metabolism in the insulin-resistant heart. <i>Acta Physiologica</i> , 2020, 228, e13430.	1.8	56
171	Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 233-242.	0.9	4
172	Drug effects on metabolic profiles of <i>Schistosoma mansoni</i> adult male parasites detected by 1H-NMR spectroscopy. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008767.	1.3	7

#	ARTICLE	IF	CITATIONS
173	Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy. <i>Pharmacological Research</i> , 2020, 160, 105176.	3.1	12
174	Hypertrophic Cardiomyopathy 2020. <i>Current Cardiology Reports</i> , 2020, 22, 154.	1.3	9
175	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2020, 76, e159-e240.	1.2	364
176	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2020, 142, e558-e631.	1.6	263
177	Unraveling the Genotype-Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity-Related Cardiac Defects as a Major Disease Modifier. <i>Journal of the American Heart Association</i> , 2020, 9, e018641.	1.6	16
178	Mitochondrial dysfunction and apoptosis underlie the hepatotoxicity of perhexiline. <i>Toxicology in Vitro</i> , 2020, 69, 104987.	1.1	10
179	Preventative therapeutic approaches for hypertrophic cardiomyopathy. <i>Journal of Physiology</i> , 2020, 599, 3495-3512.	1.3	6
180	New perspectives in the pharmacological treatment of hypertrophic cardiomyopathy. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2020, 39, 99-109.	0.2	2
181	Drug repurposing in cardiology. <i>Netherlands Heart Journal</i> , 2020, 28, 299-300.	0.3	1
182	Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart. <i>Journal of Internal Medicine</i> , 2020, 288, 491-506.	2.7	20
183	Clinical Cardiovascular Applications of Hyperpolarized Magnetic Resonance. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 231-240.	1.3	13
184	Biventricular pacemaker therapy improves exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise. <i>European Journal of Heart Failure</i> , 2020, 22, 1263-1272.	2.9	12
185	Novas perspetivas no tratamento farmacol3gico da miocardiopatia hipertr3fica. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 99-109.	0.2	3
186	Hypertrophic cardiomyopathy. <i>IJC Heart and Vasculature</i> , 2020, 27, 100503.	0.6	35
187	Increased Myocardial Oxygen Consumption Precedes Contractile Dysfunction in Hypertrophic Cardiomyopathy Caused by Pathogenic <i>TNNT2</i> Gene Variants. <i>Journal of the American Heart Association</i> , 2020, 9, e015316.	1.6	14
188	Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy. <i>Keio Journal of Medicine</i> , 2020, 69, 77-87.	0.5	4
189	Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies. <i>Cardiovascular Research</i> , 2021, 117, 694-711.	1.8	10
190	Coronary microvascular dysfunction in hypertrophic cardiomyopathy: Pathophysiology, assessment, and clinical impact. <i>Microcirculation</i> , 2021, 28, e12656.	1.0	20

#	ARTICLE	IF	CITATIONS
191	Caloric restriction mimetics for the treatment of cardiovascular diseases. <i>Cardiovascular Research</i> , 2021, 117, 1434-1449.	1.8	27
192	Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications. <i>Journal of Clinical Medicine</i> , 2021, 10, 721.	1.0	19
193	Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1260.	1.7	13
194	Design and rationale of the EMPAâ€VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2580-2590.	1.4	18
195	Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5783.	1.8	13
196	Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. <i>Current Heart Failure Reports</i> , 2021, 18, 169-179.	1.3	19
197	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, e23-e106.	0.4	33
198	Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7218.	1.8	6
200	Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1477-1482.	15.2	92
201	Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial). <i>American Heart Journal</i> , 2021, 240, 101-113.	1.2	14
203	The Failing Heart: Is It an Inefficient Engine or an Engine Out of Fuel?. , 2013, , 65-84.		4
204	How Cardiac Cytoarchitecture Can Go Wrong: Hypertrophic Cardiomyopathy as a Paradigm for Genetic Disease of the Heart. , 2015, , 227-243.		1
205	Targeted Medical Therapies for Hypertrophic Cardiomyopathy. <i>Current Cardiology Reports</i> , 2020, 22, 10.	1.3	12
206	The â€Goldilocks zoneâ€™ of fatty acid metabolism; to ensure that the relationship with cardiac function is just right. <i>Clinical Science</i> , 2017, 131, 2079-2094.	1.8	24
207	Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models. <i>JCI Insight</i> , 2018, 3, .	2.3	33
208	Mitochondrial dysfunction in pathophysiology of heart failure. <i>Journal of Clinical Investigation</i> , 2018, 128, 3716-3726.	3.9	498
209	Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets. <i>Current Pharmaceutical Design</i> , 2015, 21, 3654-3664.	0.9	92
210	Drug Therapy for Hypertrophic Cardiomyopathy: Physiology and Practice. <i>Current Cardiology Reviews</i> , 2016, 12, 52-65.	0.6	32

#	ARTICLE	IF	CITATIONS
211	An experimental approach to study the function of mitochondria in cardiomyopathy. BMB Reports, 2015, 48, 541-548.	1.1	3
212	Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy. Circulation, 2021, 144, 1714-1731.	1.6	90
213	Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment. Frontiers in Cardiovascular Medicine, 2021, 8, 722340.	1.1	15
214	Almanac 2011: Cardiomyopathies. the National Society Journals Present Selected Research That Has Driven Recent Advances in Clinical Cardiology. Acta Informatica Medica, 2011, 19, 235.	0.5	0
215	Cardiomyopathies the national society journals present selected research that has driven recent advances in clinical cardiology. Srce I Krvni Sudovi, 2012, 31, 174-180.	0.1	0
218	New Developments in Anti-Anginal Therapy: Roles of Ivabradine, Allopurinol and of Agents Modifying Myocardial Metabolism. World Journal of Cardiovascular Diseases, 2014, 04, 368-376.	0.0	0
219	Inhibition of Fatty Acid Oxidation to Treat Heart Failure in Patients. , 2014, , 249-263.		0
222	Cardiac Metabolism and Energetic Control. , 2016, , 97-134.		0
223	Medical Education and Practice in Malaysia, Quo Vadis?. Journal of Clinical and Health Sciences, 2016, 1, 1.	0.1	0
224	Molecular Mechanism of Sarcomeric Cardiomyopathies. , 2017, , 151-160.		0
226	Modulation of Cardiac Metabolism in Heart Failure. International Cardiovascular Forum Journal, 0, 17, .	1.1	1
227	Major themes for 2010 in cardiothoracic and vascular anesthesia. HSR Proceedings in Intensive Care & Cardiovascular Anesthesia, 2011, 3, 33-43.	0.6	3
228	Mitochondrial dysfunction and mitochondrial therapies in heart failure. Pharmacological Research, 2022, 175, 106038.	3.1	35
229	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2022, 24, 406-420.	2.9	22
230	Copper chelation in patients with hypertrophic cardiomyopathy. Open Heart, 2022, 9, e001803.	0.9	10
231	Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options. Cardiology and Therapy, 2022, 11, 203-230.	1.1	4
232	Serum Free Fatty Acids Independently Predict Adverse Outcomes in Acute Heart Failure Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 761537.	1.1	4
234	The promise and problems of metabolic-based therapies for heart failure.. Interventional Cardiology, 2021, 13, 415-424.	0.0	0

#	ARTICLE	IF	CITATIONS
235	Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009521.	1.6	25
236	Metabolic characterization of hypertrophic cardiomyopathy in human heart. , 2022, 1, 445-461.		8
237	Nitrates and newer antianginals. , 2013, , 38-63.		2
238	Which therapy for which condition?. , 2013, , 463-541.		1
239	Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside. <i>Drugs</i> , 2022, 82, 889-912.	4.9	18
240	Novel molecular insights and potential approaches for targeting hypertrophic cardiomyopathy: Focus on coronary modulators. <i>Vascular Pharmacology</i> , 2022, 145, 107003.	1.0	1
241	Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. <i>Cardiovascular Research</i> , 2023, 118, 3434-3450.	1.8	49
242	Mitochondrial dysfunction in heart failure and its therapeutic implications. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	9
243	Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling. <i>Biomedicines</i> , 2022, 10, 2381.	1.4	0
244	Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1027-1052.	1.9	2
245	Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature. <i>ESC Heart Failure</i> , 0, , .	1.4	2
246	Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy. <i>Hellenic Journal of Cardiology</i> , 2023, 70, 65-74.	0.4	3
247	Atorvastatin ameliorates lipid overload-induced mitochondrial dysfunction and myocardial hypertrophy by decreasing fatty acid oxidation through inactivation of the p-STAT3/CPT1 pathway. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 114024.	2.5	2
248	Targeting lipid metabolism as a new therapeutic strategy for inherited cardiomyopathies. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	0
249	Hypertrophic, Dilated, and Arrhythmogenic Cardiomyopathy: Where Are We?. <i>Biomedicines</i> , 2023, 11, 524.	1.4	6
250	Targeting mitochondria in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2023, 44, 1186-1188.	1.0	3
251	Cardiac energy metabolism in heart failure. , 2023, , 175-198.		0
252	Perhexiline: Old Drug, New Tricks? A Summary of Its Anti-Cancer Effects. <i>Molecules</i> , 2023, 28, 3624.	1.7	1

#	ARTICLE	IF	CITATIONS
258	Mechanisms and prognostic impact of myocardial ischaemia in hypertrophic cardiomyopathy. International Journal of Cardiovascular Imaging, 2023, 39, 1979-1996.	0.7	1
260	ICD for Sudden Cardiac Death Prevention and New Pharmaceutical Treatment Options in Hypertrophic Obstructive Cardiomyopathy. , 0, , .		0
262	Advances in Metabolic Remodeling and Intervention Strategies in Heart Failure. Journal of Cardiovascular Translational Research, 2024, 17, 36-55.	1.1	1